Publications by authors named "D Schonenberg-Meinema"
Objectives: In childhood-onset SLE (cSLE), patients have an increased risk of premature atherosclerosis. The pathophysiological mechanisms for this premature atherosclerosis are not yet completely understood, but besides traditional risk factors, the endothelium plays a major role. The first aim of this study was to measure levels of SLE-associated markers involved in endothelial cell (EC) function and lipids in a cSLE cohort longitudinally in comparison with healthy controls (HC).
View Article and Find Full Text PDFCapillaroscopy in the daily clinic of the pediatric rheumatologist.
Best Pract Res Clin Rheumatol
September 2024
Article Synopsis
- Nailfold capillaroscopy is becoming increasingly important in pediatric rheumatology, aiding in the diagnosis and monitoring of various conditions through a simple, non-invasive procedure.
- The review highlights essential background on capillaroscopy devices, standardized interpretations, and typical variations observed in healthy children versus those with conditions like Raynaud's phenomenon and systemic diseases.
- It also identifies gaps in current research, suggesting a need for further studies on the use of nailfold capillaroscopy in pediatric connective tissue diseases.
Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial.
Pediatr Rheumatol Online J
May 2024
Background: Etanercept has been studied in doses up to 0.8 mg/kg/week (max 50 mg/week) in juvenile idiopathic arthritis (JIA) patients. In clinical practice higher doses are used off-label, but evidence regarding the relation with outcomes is lacking.
View Article and Find Full Text PDFArticle Synopsis
- Juvenile idiopathic arthritis (JIA) is a chronic autoimmune condition in children that can lead to joint issues and often co-occurs with uveitis; adalimumab is a targeted treatment for both conditions.
- The study aimed to analyze the pharmacokinetics (PK) of adalimumab in JIA patients by comparing existing PK models and creating a new model specific to this demographic.
- Results from 50 JIA patients indicated that body weight, antidrug antibodies, and other factors influenced adalimumab clearance, with a recommended clearance rate established for more personalized treatment approaches.
Objective: To derive childhood-onset SLE (cSLE) specific remission definitions for future treat-to-target (T2T) trials, observational studies, and clinical practice.
Methods: The cSLE International T2T Task Force conducted Delphi surveys exploring paediatric perspectives on adult-onset SLE remission targets. A modified nominal group technique was used to discuss, refine, and agree on the cSLE remission target criteria.